ArticleJournal of cardiology cases2025
Rapid regression of marked left ventricular septal hypertrophy following immunosuppressive therapy in cardiac sarcoidosis.
Article in Journal of cardiology cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 46-year-old man presented with asymmetric remarkable left ventricular (LV) septal hypertrophy (maximal wall thickness: 24 mm) and complete atrio-ventricular block. Systemic sarcoidosis with a cardiac lesion was diagnosed by a supraclavicular lymph node biopsy. Following pacemaker implantation, the patient received immunosuppressive therapy with corticosteroids and methotrexate. One week after starting treatment, echocardiography and cardiac magnetic resonance (CMR) imaging showed reduced LV septal hypertrophy. At the 6-month follow-up, further thinning of the basal septal wall and enlargement of the LV with a decreased ejection fraction were observed, despite resolution of abnormal uptake in Learning objective: Cardiac sarcoidosis with asymmetrical and remarkable hypertrophy is rare in the clinical setting, and using multimodality imaging in addition to histological findings is necessary for diagnosing this condition. Multimodality imaging including echocardiography and cardiac magnetic resonance are useful for evaluating myocardial characterization and confirming remarkable changes in left ventricular wall thickness and dysfunction after immunosuppression therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.